Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (May 2021)
25 slides from Sutro Biopharma's investor presentation, May 19, 2021
Slide 1: Company Overview
Company Overview May 19, 2021 Sutro Biopharma NASDAQ: STRO Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Pioneer and Leader in Cell-Free Technology
Pioneer and Leader in Cell-Free Technology Expanding cell-free beyond ADCs 3 1 1 1 Establish cell-free ecosystem Building ecosystem through strategic partnerships Multiple ADC programs showcasing platform breadth Additional value creation through spinout New modalities and extended value creation 1
Slide 4: Industry Leading Cell-Free Protein Synthesis Platform
Industry Leading Cell-Free Protein Synthesis Platform GMP production yields consistent and scalable end-products 4 1 2 3 4 5 6 Stockpiled Extract Grow Cells from E. Coli Cell Lysis Cellular Extract Cell-Free Protein Synthesis 7 IgG with Non-Natural Amino Acids Linker-Warhead Click Chemistry Homogeno
Slide 5: Advantages of Precision Protein Therapeutics
Advantages of Precision Protein Therapeutics Homogenous, precisely designed complex biologics with optimized performance 5 Months to discover lead drug candidates using transient stable cell lines evaluating a handful of candidates Heterogeneous mixtures have less favorable therapeutic window due to
Slide 6: Cell-Free Platform is a Proven IND Engine
Cell-Free Platform is a Proven IND Engine Four product candidates in the clinic and other late-stage discovery programs in various modalities (1) (1) EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt Germany in the US (2) Sutro owns 4% royalties on net sales of VAX-24 Program Dis
Slide 7: FolRα-Targeting ADC: STRO-002
FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002
Slide 8: STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers
STRO-002 Potentially Best-in-Class ADC for Ovarian Cancers FolRα targeting ADC with tubulin inhibitor cytotoxin potentially providing immunogenic cell death STRO 002 8 STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate-receptor alpha (FolR
Slide 9: STRO-002 Part 1: Dose-Escalation Cohort in Ovarian
Study Update: Dose-escalation enrollment completed August 2020 Updated dose-escalation data as of April 23, 2021 to be presented at 2021 ASCO Annual Meeting STRO 002 Part 1: Dose-Escalation Cohort in Ovarian STRO-002-GM1 Dose-Escalation Cohort Has Been Completed Heavily pre-treated ovarian cancer pa
Slide 10: STRO-002 Was Generally Well Tolerated
STRO-002 Was Generally Well Tolerated 86% of TEAEs remain Grade 1-2 and no observed ocular toxicity signal MTD was not reached; DLTs occurred in 2 patients: Grade 2 neuropathy/Grade 3 arthralgia at 6.0 mg/kg and Grade 3 bone pain at 6.4 mg/kg Not included in table are two Grade 5 events, both previo
Slide 11: Tumor Reduction Observed in Majority of Patients
STRO 002 (1) Maximum % change from baseline in sum of longest diameter in evaluable patients treated with STRO-002 at ≥ 2.9 mg/kg (2) CR in patient treated at 2.9 mg/kg with resolution of peritoneal disease Note: Dose-escalation data as of April 23, 2021 and to be presented at 2021 ASCO Annual Meeti
Slide 12: Tumor Regression and Control Over Time
Change from baseline (%) Weeks since first treatment Treatment ongoing as of April 23, 2021 Change in Sum of Diameters for Target Lesions Over Time (N=31) (1) CR in patient treated at 2.9 mg/kg with resolution of peritoneal disease Note: Dose-escalation data as of April 23, 2021 and to be presented
Slide 13: Clinical Benefit Seen in Heavily Pre-Treated Patient Population
Weeks since first treatment Individual patients treated with STRO-002 Treatment Duration (1) and Response, Based on Evaluable Patients (N=31) Clinical Benefit Seen in Heavily Pre-Treated Patient Population Median duration of response is 5.8 months and three patients remained on study at over 18 mont
Slide 14: Favorable PFS Compared to Chemotherapy and Other Agents
STRO 002 Favorable PFS Compared to Chemotherapy and Other Agents Based on Kaplan-Meier estimates, median PFS was 7.2 months PFS is calculated on 39 patients from the time from the first dose of study treatment until the time of death or progressive disease (PD) whichever occurs first. If no death or
Slide 15: FolRα-Expression by Immunohistochemistry
STRO 002 FolRα-Expression by Immunohistochemistry Responses and anti-tumor activity observed across various FolRα-expression levels Best Overall Response (BOR) Assessed by Ventana FOLR1 expression assay based on available archival tissue from dose-escalation patients and scored using H-score and PS2
Slide 16: Path Forward for STRO-002 Clinical Development
STRO 002 Path Forward for STRO-002 Clinical Development Next steps for moving towards registration-directed study Part 2: Dose-Expansion Cohorts (Ovarian & Endometrial) FolRα-Selected Endometrial Cancer Relapsed/refractory disease No standard of care treatment All-Comers Ovarian Cancer Tissue requir
Slide 17: CD74-Targeting ADC: STRO-001
CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001
Slide 18: Potential First-in-Class Molecule for Patients with NHL and MM
Potential First-in-Class Molecule for Patients with NHL and MM Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects STRO 001 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: CD74 is expressed in many
Slide 19: STRO-001-BCM1 Dose-Escalation Study
STRO-001-BCM1 Dose-Escalation Study STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose-escalation study with NHL update at ASH 2020 STRO 001 NHL Cohort Update at ASH 2020 A total of 21 patients have been treated with STRO-001 and 18 patients were evaluable for response as of October 30, 202
Slide 20: ASH 2020 Update in NHL Cohort
Note: Data as of October 30, 2020 from ASH 2020 ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies STRO 001 20
Slide 21: Responses to STRO-001 Treatment Duration
Responses to STRO-001 Treatment Duration Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL patients who had progressed on CAR-T STRO 001 (1) 18 patients are evaluable for response as of October 30, 2020 Note: Data as of October 30, 2020 from ASH 2020 21
Slide 22: Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer
Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer (1) Novel and precise design to drive adaptive and protective immune responses Conjugated Antibody Cytokine Derivative Enhanced tumor targeting of cytotoxic payloads Prodrug cytokine targeting functional cytokine to tumor Bispecifi
Slide 23: Financial Overview
Financial Overview Well-capitalized through cash and other financial sources $294.9M in cash, cash equivalents & marketable securities as of March 31, 2021 Projected cash runway into 2H 2023 , not including potential monetization of Vaxcyte shares or future BD ~1.6M shares of Vaxcyte (Nasdaq: PCVX)
Slide 24: Driving Value Through Advancing Programs
Driving Value Through Advancing Programs Multiple opportunities to impact value into 2021 and beyond 24 ✔ ✔ ✔
Slide 25: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini Chief Financial Officer Shabbir Anik, PhD Chief Technical Operations Officer Linda Fitzp